StreetAlpha.app
Home › Stocks › CNSY

Cerenome, Inc. (CNSY)

$0.63
▼ −10.29%
LAST CLOSE · NOV 20

Plus Therapeutics develops diagnostic tests and targeted radiation treatments for cancers of the central nervous system. It last closed at $0.63 on Nov 20, down 10.29% on the day. The next earnings report for CNSY is expected around Thu, Mar 11, 2027, after the close. For the quarter ended Sep 2026, CNSY reported EPS of -$1.14 on revenue of $722,000, with revenue down 48.3% from a year ago. Over its last 3 reports the stock moved an average of 16.4% the session after earnings.

AI Auto Pilots
Is CNSY in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CNSY.

Key Stats

Last 12 months
Results
Revenue
$3.5M
−32.9% vs a year ago
Net income
−$30.3M
−859.5% margin
Free cash flow
−$28.7M
−813.5% margin
Operating margin
−832.6%
−$29.4M operating income
Valuation
Market cap
$6.2M
9.8M shares
P/E
–
Price to sales
1.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$879K
At Sep 30
Shareholder equity
−$923K
Shares outstanding
9.8M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $4.9M$4.9MFY2023FY2024: $5.8M$5.8MFY2024FY2025: $5.2M$5.2MFY2025

From CNSY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Mar 11
Estimated date · After the close
Reported EPS
-$1.14
Quarter ended Sep 2026
Year ago EPS
-$1.03
Same quarter last year
Revenue
$722,000
−48.3% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.67Dec '24Mar 2025: -$29.86Mar '25Jun 2025: -$0.16Jun '25Sep 2025: -$1.03Sep '25Dec 2025: $6.92Dec '25Mar 2026: -$1.05Mar '26Jun 2026: -$1.31Jun '26Sep 2026: -$1.14Sep '26Latest -$1.14
Revenue by quarter
Dec 2024: $1.4MDec '24Mar 2025: $1.1MMar '25Jun 2025: $1.4MJun '25Sep 2025: $1.4MSep '25Dec 2025: $1.4MDec '25Mar 2026: $1.0MMar '26Jun 2026: $411,000Jun '26Sep 2026: $722,000Sep '26Latest $722,000
How CNSY moved after its last 3 reports
Average move the session after a report ±16.4%
Nov 13, 2026After the close−24.8%
Aug 14, 2026After the close−13.0%
May 15, 2026After the close+11.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CNSYStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CNSY
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CNSY

Technical Analysis

CNSY · as of the Nov 20 close · updated each morning
Falling, nearing oversold

The stock is 65% below its 20 day and 141% below its 50 day average. Momentum is fading (RSI 32), near oversold. The nearest support is the swing low (Nov 17) at $0.60, and the nearest resistance the Pivot at $0.67.

Short trendBearish
Long trendNot enough history
MomentumFading
StretchNear oversold
VolatilityHigh, 42.0%/day
Key levels
$8.0052 week high+1169.8%
$2.50100 day average+296.8%
$1.5250 day average+141.3%
$1.18Swing high (Nov 13)+87.3%
$1.0420 day average+65.1%
$0.70Pivot R1+11.1%
$0.67Pivot+6.3%
$0.63Last close
$0.60Swing low (Nov 17)−4.8%
$0.59Pivot S1−6.3%
$0.4352 week low−31.7%
Indicators
RSI (14)32.20Weak, oversold below 30Neutral
MACD-0.29Below its signal lineBearish
Stochastic6.6Near the bottom of its rangeOversold
ADX (14)33.3Trending up
Williams %R-94.7Oversold below −80, overbought above −20Oversold
CCI (20)-61.9Oversold below −100, overbought above 100Neutral
Rate of change−2.0%Change over 10 sessionsBearish
ATR (14)$0.26Typical daily range, 42.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for CNSY

What happened before

See how CNSY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for CNSYHow many large options trades hit CNSY, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CNSY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●8 buying vs 9 selling
  • ●Held by funds -0.0 pts
  • ▲Funds holding +1
  • ▼Superinvestors: 0 added, 1 cut
  • ●Put/call not meaningful
Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2221+4.8%
In funds' top 1000–
Held by funds6.4%6.4%−0.0 pts
New / increased5 / 318 / 0−55.6%
Reduced / sold out5 / 41 / 0+800.0%
Put/call ratio–––
SuperinvestorsKen GriffinSold out
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CNSY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CNSY Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 4, 2025Andrew John Hugh MacIntyre SimsCFOBuy20,000$0.51$10K
Aug 22, 2025Robert P LenkDirectorBuy110,000$0.49$54K
Every insider buy and sale for CNSY over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CNSY insider trades →

From SEC Form 4 filings by CNSY's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CNSY is in one of them and how their past CNSY trades turned out.

CNSY in the AI portfolios
Loading…

CNSY News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CNSY in an article yet. Here's the latest on the wider market.

CNSY in the news

About Cerenome

Plus Therapeutics is a U.S. healthcare company based in Houston, Texas, that develops precision diagnostic tests and targeted radiopharmaceutical treatments for cancers of the central nervous system. Its CNSide Test is a laboratory developed test that identifies cancer cells spread to the brain and spinal fluid in patients with carcinomas and melanomas, and it is offered through national insurance agreements. Its lead drug candidate, rhenium (186Re) obisbemeda, is designed to deliver radiation directly into brain tumors such as recurrent glioblastoma and leptomeningeal metastases. The company is also developing a second radiotherapy candidate for liver cancers.

Headquarters
Houston, TX
Founded
1996